Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robert H. Hyland, DPhil
Gilead Sciences
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Fundacion de Investigacion de Diego
Santurce, Puerto Rico, Puerto Rico
- Quest Clinical Research
San Francisco, California, United States
- University of Florida
Gainesville, Florida, United States
- Orlando Immunology Center
Orlando, Florida, United States
- Duke University
Durham, North Carolina, United States
- Alamo Medical Research Center
San Antonio, Texas, United States
- Virginia Mason Medical Center
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2010
- Primary completion
- 30 Apr 2010
- Completion
- 31 Aug 2011
- Last update posted
- 17 Apr 2014
- Registered enrollment
- 64
- Registry id
- NCT01054729
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.